Previous close | 400.16 |
Open | 401.50 |
Bid | 400.88 x 100 |
Ask | 401.17 x 100 |
Day's range | 397.59 - 405.67 |
52-week range | 320.01 - 448.40 |
Volume | |
Avg. volume | 1,115,022 |
Market cap | 103.663B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 28.90 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On May 2, 2024, Director Sangeeta Bhatia sold 467 shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) as reported in a recent SEC Filing.
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close.
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.